INBX compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

INBXInhibrx Biosciences, Inc.

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

INBXInhibrx Biosciences, Inc.

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

INBXInhibrx Biosciences, Inc.

80.55▲+11.62%

Mkt cap$1.1BRevenue$1MQ2 FY25Revenue—

AMGNAmgen Inc

464.19▼−0.27%

Regular sessionNov 3 '26

Mkt cap$251.6BRevenue$10.1BQ2 FY26Revenue$36.8BFY25

Compare

Regular sessionNov 3 '26

INBXInhibrx Biosciences, Inc.

AMGNAmgen Inc

80.55▲+11.62%

Price

464.19▼−0.27%

$1.1B

Mkt cap

$251.6B

Q2 FY25$1M

Revenue

$10.1BQ2 FY26

—

Revenue

$36.8BFY25

INBX80.55▲+11.62%vsAMGN464.19▼−0.27%Regular sessionNov 3 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

INBX: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only INBX 4

REGNRegeneron Pharmaceuticalscustomer

SNYSanoficustomer

—Scitheraunlistedcustomer

—Art Acquisition Subunlistedcustomer

Shared 0

No shared counterparties.

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

8 more · AMGN chain ›

Price

rebased to 0%

INBX, solidAMGN, dashed